News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedic

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica29/11/2016Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases announces today that it has entered into a strategic alliance with Oxford BioMedica plc (“Oxford BioMedica”) (LSE: OXB), a world-leading company in gene and cell therapy.Under the terms of the collaboration and lice


2. Charnwood Molecular Appoints New Head of Medicinal Chemistry

Charnwood Molecular Appoints New Head of Medicinal Chemistry14/12/2016Loughborough, UK – CRO, Charnwood Molecular Ltd, appoints Dr James Hitchin as its new Head of Medicinal Chemistry to lead its research services laboratories at BioCity, Nottingham.Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team.  James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy.  Most recently he was S


3. The BioHub Birmingham® Hosts National Life Science Event: BioBrum – 16

The BioHub Birmingham® Hosts National Life Science Event: BioBrum – 16th February 201715/12/2016Birmingham, UK – The BioHub Birmingham®, Birmingham’s flagship life science incubator, is hosting its first BioBrum Life Science event on 16th February 2017.  Aimed at pre-revenue life science companies the free event will include talks on finance, intellectual property, effective use of professional networks and business development.  There will also be an o


4. Takeda to Acquire ARIAD Pharmaceuticals, Inc. 

Takeda to Acquire ARIAD Pharmaceuticals, Inc.09/01/2017Cambridge, USA & Osaka, Japan – Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expecte


5. AMSBIO Launches New Ready-to-use Adeno-Associated Virus Biosensors

AMSBIO Launches New Ready-to-use Adeno-Associated Virus Biosensors19/01/2017 Abingdon, UK – AMSBIO announce a new range of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encode your chosen biosensor, either calcium or glutamate sensor and are ready for in vivo injection.The new range of Calcium or Glutamate biosensor products comes with a choice of promoter and the ability to include the Cre inducible (FLEx-ON) expression. AMSBIO have packaged these indica



Page 19 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018